Oxford Genome Sciences

Oxford BioTherapeutics is a clinical-stage oncology company specializing in the discovery and development of novel antibody-based therapies, including antibody-drug conjugates (ADCs) and immuno-oncology agents. The company utilizes its proprietary OGAP® (Oxford Genome Anatomy Project) database, a massive proteomic resource, to identify and validate unique targets for cancer treatment. Its lead programs target difficult-to-treat cancers such as triple-negative breast cancer and various solid tumors. Oxford BioTherapeutics maintains a robust network of strategic partnerships with global pharmaceutical leaders to accelerate its pipeline through clinical development. The company operates from facilities in Oxford, UK, and San Jose, California.